Search

Argenx SE

Geschlossen

BrancheGesundheitswesen

739.4 -0.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

745.2

Max

749.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

455M

821M

Verkäufe

1.5B

2.8B

KGV

Branchendurchschnitt

33.955

64.641

EPS

7.32

Gewinnspanne

29.79

Angestellte

1,863

EBITDA

70M

829M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-2.07% downside

Dividenden

By Acuity

Nächstes Ergebnis

22. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.7B

49B

Vorheriger Eröffnungskurs

740.28

Vorheriger Schlusskurs

739.4

Nachrichtenstimmung

By Acuity

50%

50%

138 / 340 Ranking in Healthcare

Argenx SE Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Aug. 2026, 19:01 UTC

News
Correlated Moves

Ethereum is trading lower, reflecting a broader decline in correlated assets. It remains below its 20-day moving average amid routine market fluctuations.

1. Aug. 2026, 00:06 UTC

Social Media
News

TLT trades lower in after-market hours, reflecting a historically bearish period for bonds and targeting the $80 level amid rising interest rate expectations.

1. Aug. 2026, 00:06 UTC

News

Geopolitical tensions with Iran have boosted the United States Oil Fund LP, following President Trump's ordered military offensive in response to attacks on U.S. troops.

1. Aug. 2026, 00:06 UTC

News

Ameriprise Financial Inc shares are lower in after-market trading, despite strong second-quarter revenue of $4.90 billion and adjusted EPS of $11.07.

1. Aug. 2026, 00:02 UTC

News

UBS raised its price target on Hershey Co to $198, maintaining a Neutral rating. Shares are trading higher during after-market hours.

1. Aug. 2026, 00:02 UTC

News

Lattice Semiconductor shares are lower in after-market trading following a cautionary report citing declining sales and rising costs, with shares priced at $124.53.

1. Aug. 2026, 00:02 UTC

News

Snap Inc. shares rose to about $4.70 in after-market hours, supported by bullish options activity ahead of its August 3 earnings report.

1. Aug. 2026, 00:02 UTC

News
Social Media

NVIDIA Corp shares are lower in after-market hours amid broader market declines, despite recent strong performance relative to peers and a weekly gain.

1. Aug. 2026, 00:02 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blade design, boosting shares in after-market hours.

1. Aug. 2026, 00:02 UTC

News
Correlated Moves

JPMorgan Chase & Co shares are lower in after-market trading amid ongoing market rotation and rising bond yields affecting investor sentiment.

1. Aug. 2026, 00:02 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion. Shares declined in after-market trading despite strong earnings and net income growth.

1. Aug. 2026, 00:02 UTC

News

Exponent Inc shares are trading lower in after-market hours after UBS lowered its price target to $72 while maintaining a Neutral rating.

1. Aug. 2026, 00:02 UTC

News

Bloom Energy Corp is declining in after-market hours amid a class action lawsuit alleging securities fraud and broader market pressures.

1. Aug. 2026, 00:01 UTC

News

Quantum Corp shares are higher in after-market trading, supported by positive developments in the quantum computing industry and strong investor interest in the sector.

1. Aug. 2026, 00:01 UTC

News

UBS raised its price target on Bright Horizons to $88, as shares gain in after-market trading following three sessions of declines.

1. Aug. 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

1. Aug. 2026, 00:01 UTC

News

Newell Brands Inc shares are lower in after-market hours amid overall market declines. The company entered a five-year credit facility of up to $800 million.

1. Aug. 2026, 00:01 UTC

News

UBS raised its price target on Valero Energy Corp to $355, contributing to shares' gain during after-market hours on Friday.

1. Aug. 2026, 00:01 UTC

News

UBS maintains Buy rating on Saia Inc, lowering price target to $504. Shares are higher in after-market trading following the adjustment.

1. Aug. 2026, 00:01 UTC

News

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

1. Aug. 2026, 00:01 UTC

News

American Electric Power reported Q2 earnings of $1.36 per share and raised its 2026 guidance to $6.25 to $6.55, driving shares higher in after-market hours.

1. Aug. 2026, 00:01 UTC

News

Clean Energy Fuels Corp is trading lower in after-market hours following a cautionary analysis highlighting its subpar revenue growth and high production costs.

1. Aug. 2026, 00:01 UTC

News

Chevron Corp has reached an accord with Iraq to invest in two oil fields, enhancing production capabilities. Shares are trading higher in after-market hours.

31. Juli 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31. Juli 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31. Juli 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31. Juli 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31. Juli 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31. Juli 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31. Juli 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

Peer-Vergleich

Kursveränderung

Argenx SE Prognose

Kursziel

By TipRanks

-2.07% Nachteil

12-Monats-Prognose

Durchschnitt 438.33 EUR  -2.07%

Hoch 545 EUR

Tief 223 EUR

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Argenx SE – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

5

Buy

0

Halten

1

Sell

Stimmung

By Acuity

138 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
help-icon Live chat